- Inconclusive Efficacy of Vitamin D Supplementation: The research, through a systematic review and meta-analysis, reveals that vitamin D supplementation's efficacy and safety in treating psoriasis could not be determined due to insignificant findings. Three of the four selected studies failed to demonstrate significant efficacy, attributing small changes to factors other than vitamin D supplementation.
- Psoriasis Prevalence and Severity: More than 100 million people worldwide live with psoriasis, and the majority (78% to 90%) of diagnosed patients exhibit mild to moderate skin lesions.
- Controversy in Vitamin D Treatment: Despite being used since 1985 to treat psoriasis, the article underscores the controversy surrounding the effectiveness of vitamin D. The debate extends to the comparative effectiveness of vitamin D2 (from plants) and vitamin D3 (from animals), with a suggestion that vitamin D2 might be more beneficial, though not significantly.
- PASI Values and Time Frame: The study analyzed the Psoriasis Area and Severity Index (PASI) values at different time points. At 3 months, vitamin D supplementation did not significantly affect PASI values. At 6 months, there was a significant effect, but no significant difference in heterogeneity. At the follow-up, vitamin D supplementation, especially vitamin D2, appeared more effective than vitamin D3.
- Safety Issues and Dosage Variability: Only two out of five studies reported adverse events related to vitamin D supplementation, with nausea being the notable side effect. The article highlights the challenges in determining a conclusive dosage for vitamin D supplementation. The recommended daily dose range is wide (4000 – 10,000 IU/day), and the study suggests that the heterogeneity in dosage makes it challenging to draw definitive conclusions about safety, despite existing studies not suggesting safety concerns. The article emphasizes the need for further exploration of dosage and its relationship to safety.